Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 19/20 | 0.92 |
| ▸ | ABCG2 | Q9UNQ0 | 17/20 | 0.92 |
| ▸ | ABCC1 | P33527 | 15/20 | 0.92 |
| ▸ | SCN1A | P35498 | 1/20 | 0.76 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.76 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459996 | 1.00 | ABCB1 (0.92) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| Hexobendine SCHEMBL125629 | 0.87 | SCN1A (1.00) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| Hexobendine SCHEMBL317378 | 0.86 | SCN1A (0.97) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| Hexobendine SCHEMBL2459088 | 0.86 | SCN1A (0.97) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| Hexobendine SCHEMBL10402178 | 0.86 | SCN1A (0.97) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| SCHEMBL2455198 | 0.82 | SLC29A1 (0.77) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| SCHEMBL2455200 | 0.82 | SLC29A1 (0.77) | ABCB1ABCG2ABCC1SCN1ASCN2A | |
| SCHEMBL17459720 | 0.79 | ALOX5 (0.67) | ABCB1ABCG2ABCC1 | |
| SCHEMBL17459718 | 0.79 | ALOX5 (0.67) | ABCB1ABCG2ABCC1 | |
| SCHEMBL2459622 | 0.78 | SCN1A (0.82) | ABCB1ABCG2ABCC1SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | ABCB1 3111/4885ABCG2 4722/4885ABCC1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.